A study analyzed the cost-effectiveness of two different treatment methods in NSCLC. Results of a study explored the potential of automated lung tumor vascularity. A study assessed unmet needs as well as QOL and FT in survivors of NSCLC. A study assessed differences in lung cancer screening eligibility among lung cancer survivors. Researchers evaluated the safety, tolerability, and antitumor activity of Dato-DXd in treating NSCLC. After an IPPC, the incidence of second primary lung cancer is high among never-smokers. Smoking cessation services can be successfully integrated into low-dose computed tomography lung cancer screening programs. Researchers from the US and Italy have identified a biomarker that can distinguish between SCLC and SCC. The level of serum ferritin in a patient with lung cancer is an effective prognostic factor for the disease. Removal of race correction in PFTs is a priority to address the inappropriate use of race within algorithms. Depression is common in patients with lung cancer and those with type 2 diabetes. VOCs are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. Within the lung cancer realm, different types of AI are being applied to advance the understanding of the disease. A study examined the impact of the Interception-Lung program, which aims to reduce the incidence of advanced lung cancer. A study evaluated the prognosis of patients with locally advanced and metastatic NSCLC who underwent prior TKI. The study aimed to investigate the relationship between tobacco use and lung cancer. The TROPION-Lung07 trial will evaluate Dato-DXd plus pembrolizumab in patients with advanced/metastatic NSCLC. Marisa Bittoni, PhD, talks about a large-scale study exploring factors that lead to lung cancer in patients younger than 50. Patients with NSCLC who have NTRK mutations have a survival advantage with immune checkpoint inhibitors. The first in-human study of datopotamab deruxtecan showed the optimal dose for treating NSCLC.